This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The pate
This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The patent application further relates to the use of Rotigotine in the production of the cement layer of a TTS by a hot-melt method.
대표청구항▼
1. A transdermal therapeutic system (TTS) comprising an active-substance-containing cement matrix, wherein the cement matrix comprises a hot-meltable adhesive in which the active substance is dispersed and melted using a hot-melt process, and wherein the active substance is rotigotine and is partly
1. A transdermal therapeutic system (TTS) comprising an active-substance-containing cement matrix, wherein the cement matrix comprises a hot-meltable adhesive in which the active substance is dispersed and melted using a hot-melt process, and wherein the active substance is rotigotine and is partly or completely dissolved in the adhesive; and wherein the hot-melt process comprises melting and homogenizing components of the cement matrix and rotigotine without solvent in an extruder at a temperature between 120° C. and 160° C. prior to lamination of the cement matrix. 2. The TTS of claim 1, wherein the hot-meltable adhesive comprises an amine-resistant silicone adhesive and, in mixture therewith, at least one pharmaceutically acceptable softener. 3. The TTS of claim 2, wherein the at least one softener is an organic wax. 4. The TTS of claim 2, wherein the at least one softener is ceresine or ozokerite. 5. The TTS of claim 1, wherein the cement matrix comprises 4-40 weight % rotigotine. 6. The TTS of claim 1, wherein the cement matrix comprises 9-30 weight % rotigotine. 7. The TTS of claim 1, wherein the cement matrix comprises 20-40 weight % rotigotine. 8. The TTS of claim 1, wherein the rotigotine is present in free-base form. 9. The TTS of claim 1, wherein the active-substance-containing cement matrix further comprises an internal-phase component selected from the group consisting of (a) hydrophilic and amphiphilic polymers and mixtures thereof with pharmaceutically acceptable softeners,(b) hydrophilic and amphiphilic copolymers and mixtures thereof with pharmaceutically acceptable softeners,(c) condensates of glycerin and fatty acids,(d) condensates of glycerin and polyols, and(e) mixtures of components (a)-(d). 10. The TTS of claim 1, wherein the active-substance-containing cement matrix further comprises at least one internal-phase component selected from the group consisting of polysaccharides, substituted polysaccharides, polyethylene oxides, polyvinyl acetates, polyvinyl pyrrolidones, copolymers of polyvinyl pyrrolidone and polyvinyl acetate, polyethylene glycol, polypropylene glycol, copolymers of ethylene and vinyl acetate, glycerin-fatty acid esters and mixtures of polyvinyl alcohol with glycerin. 11. The TTS of claim 1, wherein the cement matrix comprises (a) 50-99 weight % of a hot-meltable adhesive,(b) 4-40 weight % of rotigotine,(c) 0-40 weight % of an internal-phase component, and(d) 0-10 weight % of other adjuvants. 12. The TTS of claim 11, wherein the hot-meltable adhesive is an EVA adhesive, an SXS adhesive, or a mixture of (i) 70-99 weight % of an amine-resistant silicone adhesive and (ii) 1-30 weight % of a pharmaceutically acceptable softener. 13. The TTS of claim 11, wherein the rotigotine is present in an amount effective, upon application of the TTS on skin of a human patient, to induce an average plasma concentration of 0.4 to 2 ng/ml rotigotine in the patient for a period of at least 5 days following said application. 14. The TTS of claim 13, wherein the rotigotine is present in an amount effective to induce an average plasma concentration of 0.4 to 2 ng/ml rotigotine in the patient for a period of at least 7 days following said application. 15. The TTS of claim 1, wherein the rotigotine is present in an amount effective, upon application of the TTS on skin of a human patient, to provide transport of rotigotine through the skin at a steady-state flux rate of 200-300 μg per hour. 16. A method for preparing a TTS that comprises a rotigotine-containing cement matrix, the method comprising: melting and homogenizing components of the cement matrix and rotigotine without solvent in an extruder at a temperature between 120° C. and 160° C. prior to lamination of the cement matrix. 17. The method of claim 16, wherein the method is a two-step method comprising: melting and homogenizing components of the cement matrix other than rotigotine without solvent, andintroducing rotigotine at a temperature between 120° C. and 160° C., into the melted cement matrix. 18. The method of claim 17, wherein the rotigotine is introduced in solid state into the melted cement matrix. 19. The method of claim 17, wherein the rotigotine in the cement matrix has a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm. 20. The TTS of claim 1, wherein the rotigotine is present in a therapeutically effective amount for treatment of a disease associated with a dopamine-metabolism disorder in a human patient, by application of the TTS on skin of the patient. 21. The TTS of claim 20, wherein the disease associated with a dopamine-metabolism disorder is Parkinson's disease. 22. The TTS of claim 20, wherein the disease associated with a dopamine-metabolism disorder is restless leg syndrome. 23. A method for treating a disease associated with a dopamine-metabolism disorder in a human patient, comprising applying to skin of the patient a TTS of claim 1 in a therapeutically effective amount. 24. The method of claim 23, wherein the disease associated with a dopamine-metabolism disorder is Parkinson's disease. 25. The method of claim 23, wherein the disease associated with a dopamine-metabolism disorder is restless leg syndrome.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (62)
Merkle Hans P. (Zurich CHX) Nagels Klaus (Bonn DEX) Schacht Dietrich (Cologne DEX) Wolff Hans-Michael (Monheim DEX), Active ingredient patch for low-melting and/or volatile active ingredients.
Jaeger Halvor (Neu-Ulm DEX) Hoffmann Hans-Rainer (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Klein Robert-Peter (Neuwied DEX), Apparatus for the delivery of substances, processes for the production thereof and use thereof.
Thomas E. Conn ; Russell Ford ; Pravin L. Soni ; Michael J. Tierney ; Prema Vijayakumar, Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems.
Gueret Jean-Louis H.,FRX, Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbi.
Michael J. Butler ; Thomas E. Conn ; David M. Liu ; Norman A. Parris ; Michael Reidy ; Pravin L. Soni, Device and methods for the application of mechanical force to a gel/sensor assembly.
Wong Ooi (Fremont CA) Nguyen Thuytien N. (Hayward CA), Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters.
Hoffmann Hans-Rainer (Neuwied DEX) Klein Robert P. (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Cordes Gunter (Leichingen DEX) Wolff Hans M. (Monheim DEX), Estrogen-containing active substance plaster.
Roreger Michael (Neuwied DEX) Herrmann Fritz (Neuwied DEX) Hoffmann Hans-Rainer (Neuwied DEX) List Harald (Neuwied DEX), Flexible, hydrophilic gel film, the process for its production and the use of it.
Rimpler,Stephan; Grapatin,Sabine; Krein,Cliff; Thelen,Markus, Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients.
Roos Eric J. (Marlborough MA) Chiang Chia-Ming (Foster City CA) Hsu Tsung-Min (Taipei TWX), Low flux matrix system for delivering potent drugs transdermally.
Colley Kenneth J. (San Francisco CA) Wilson Donald R. (San Francisco CA) Cleary Gary W. (San Mateo CA) Lammintausta Risto (Turku FIX) Jalonen Harry (Turku FIX), Method and device for administering dexmedetomidine transdermally.
Maignan Jean (Tremblay les Gonesse FRX) Malle Grard (Villiers sur Morin FRX) Deflandre Andr (Orry-La-Ville FRX) Lang Grard (Saint Gratien FRX), New derivatives of 5,6,7,8-tetrahydro-1-naphthalenol, a process for their preparation and cosmetic and pharmaceutical co.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Chen Tung-Fen ; Chiang Chia-Ming ; Jona Janan ; Joshi Priti ; Ramdas Asha, Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufactu.
Sylvia Rossi-Montero ; Juan Mantelle ; David Kanios ; David Houze, Solubility enhancement of drugs in transdermal drug delivery systems and methods of use.
Fallon Renee A. (Sunnyvale CA) Venkatraman Subbu S. (Palo Alto CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset.
Venktrama Subbu S. (Palo Alto CA) Fallon Renee A. (Sunnyvale CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset.
Chiang Chia-Ming (Foster City CA) Colley Kenneth J. (Washington DC) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset.
Ma Xinghang ; Audett Jay ; Soni Pravin L. ; Singh Noel ; Bailey Susan E., Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Muller, Walter; Peck, James V., Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Bouwstra, Johanna Aaltje; Ackaert, Oliver; Eikelenboom, Jacob; Wolff, Hans-Michael, Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.